HOME >> BIOLOGY >> NEWS
Promising research: From employment issues to virology

The twelve new Priority Programmes to be funded by the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) from the beginning of 2005 onwards cover such topics as the use of concrete, cultures in the Middle Ages, astrophysics and the kinships of animals. The Senate of the DFG selected them from among 80 applications and will provide a total of 32.6 million to support them during the first two years. This raises the number of Priority Programmes funded in the year 2005 to a total of 109. The DFG uses Priority Programmes to bring together researchers from different research institutions on certain projects in develop-ing fields of research. As a rule, Priority Programmes run for six years.

The new Priority Programmes are:

Life Sciences

The Priority Programme "Membranes Enveloping Virus Particles and Cellular Struc-tures" unites the fields of cell biology and virology. It deals with viruses and cell organelles and examines the joint mechanisms that cause organelles and viruses to be enveloped by membranes. The basic researchers also focus on the application. Understanding the principles of envelopment could lead to the development of new intervention strategies. This priority is meant to unite virologists, cell biologists, biochemists, structural biologists and biophysicists. The viruses being examined include important aetiological agents that infest humans, such as HI, Ebola, hepatitis C or herpes viruses.
(Coordinator: Professor Dr. Hans-Georg Krulich, University of Heidelberg)

The aim of the Priority Programme "Phylogeny of Animals Deep Metazoan Phylogeny" is to clarify whether the classification of animals, including sea sponges and arthropods, such as insects, and coelom animals, was previously misguided because the only possible means of sorting them was according to the shape of their body and their internal characteristics. It could be that a methodically critical view of both morphological as well
'"/>

Contact: Dr. Cornelia Pretzer
cornelia.pretzer@dfg.de
49-228-885-2376
Deutsche Forschungsgemeinschaft
21-May-2004


Page: 1 2 3 4 5 6

Related biology news :

1. Promising hospital anti-infection strategy probably wont work, study shows
2. Promising new tool shows how dividing cells finish what they start
3. Promising biomarker for melanoma is identified
4. Promising multi-strain HIV vaccine candidate emerges
5. Promising new therapies for deadly form of leukemia
6. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
7. SFU Spin-Off Company To Research Promising Antibacterial Agents
8. SFU Molecular Biologist Pursues Promising New Way To Fight Disease
9. UNC-CH Researchers Develop Promising Heart Research Tool
10. Duke Researchers Call Gene Therapy A Promising Strategy For Sickle Cell Anemia
11. Promising Fatty Acid Research Leads To MS Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising research From employment issues virology

(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
Cached News: